Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor?

Tyrosine kinase receptor inhibitors (TKIs) are a relatively new class of targeted anti-cancer agents with vascular endothelial growth factor signalling pathway–inhibiting properties. Hypertension is recognized as one of the most common adverse effects of this anti-angiogenic therapy and is the conse...

Descripción completa

Detalles Bibliográficos
Autores principales: Ptinopoulou, Anastasia G., Sprangers, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Editorial Comments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857807/
https://www.ncbi.nlm.nih.gov/pubmed/33564402
http://dx.doi.org/10.1093/ckj/sfaa174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857807/
https://www.ncbi.nlm.nih.gov/pubmed/33564402
http://dx.doi.org/10.1093/ckj/sfaa174

Ejemplares similares